Compare Enveric Biosciences Inc (ENVB) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs New York Times Co — how do they compare? Enveric Biosciences Inc trades at $1.43 (market cap $5.32M), while New York Times Co trades at $76.05 (market cap $12.18B). The key difference: New York Times Co is far larger — about 2289.5× Enveric Biosciences Inc's market cap, and New York Times Co pays a 1.22% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | NYT | |
|---|---|---|
Market Cap | $5.32M | $12.18B |
Sector | Health | Media |
52-Week High | $17.40 | $85.86 |
52-Week Low | $1.28 | $51.43 |
Enterprise Value | $408.82K | $11.57B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
The New York Times (NYT) trades at $75.85, up 3.93% today, showing strong momentum with consistent earnings beats in recent quarters. Technicals are bullish with support at $75 and resistance at $76. Revenue grew to $2.82B in 2025, with net income margin expanding to 12.17%. The company maintains robust cash flow from operations at $584M and announced a $0.23 dividend payable July 23, 2026.
Outlook remains positive with Q2 2026 earnings expected at $0.67 EPS on August 5. Analysts project a $78 consensus target, though legal pressures from government subpoenas and OpenAI copyright disputes pose near-term risks. Valuation multiples like P/E of 32.28 suggest premium pricing relative to historical norms, requiring sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
